A Mechanistic Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol
ConditionHypertriglyceridemia
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorMarea Therapeutics
About this trial
The primary objective of the study is to determine the effect of MAR001 as compared to placebo on levels of the triglycerides (TG) in the postprandial state in adults with elevated TG.
Eligibility criteria
Qualifiers
Willingness to provide informed consent and comply with the intervention and all study assessments
Two fasting TG collected at two separate, consecutive visits at least 7 days apart during the Screening period
HbA1c ≥ 5.7% and ≤ 8.5%
Stable diet for a minimum of 3 months prior to screening and with no plans to change diet through duration of study
Disqualifiers
Acute or chronic liver disease
Diabetes medications (other than metformin)
History of type 1 diabetes mellitus or history of diabetic ketoacidosis
Newly diagnosed T2DM
Trial design
Treatments tested in this trial
- MAR001
- Placebo
Treatment groups
30 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov